Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema

Part of paid clinical trials in New York, New York.

Sponsor
Vitreous -Retina- Macula Consultants of New York
Study ID
NCT00403039
Phase
PHASE1
Status
Completed

Conditions

  • Retinal Vein Occlusion

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to examine the effects of Lucentis for active Central Retinal Vein Occlusion with Macular Edema

Key Dates

First listed
Nov 23, 2006
Start date
Nov 30, 2006
Status verified
Dec 2015
Primary completion
Dec 31, 2011
Completion
Dec 31, 2011

Study Design

Enrollment
41 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Open-label ranibizumab
    Subjects will receive open-label intravitreal injections of ranibizumab administered every 28 ± 7 days for a total of 3 injections. Thereafter they are to be evaluated monthly for re-treatment until Month 48.

Primary Outcome Measure

To determine the safety and tolerability of 0.5 mg dose of Ranibizumab in the treatment of Macular Edema associated with CRVO [ Time Frame: 72 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Vitreous Retina Macula Consultants of New York, P.C.New YorkNew York10022-

Find similar trials in New York, NY

By research site
Vitreous Retina Macula Consultants of New York, P.C.· New York, NY

Related Studies